GA-STONEBRANCH
27.2.2024 19:25:26 CET | Business Wire | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, announced another year of significant growth and innovation. Building on the unprecedented success of 2022, Stonebranch has continued to expand its offerings with major product updates and a host of strategic integrations that solidify its position as a leader in the IT automation industry.
New Customer and Partner Relationships Fuel Growth
In 2023, Stonebranch significantly expanded its customer base, welcoming a diverse range of new clients from various sectors, including finance, healthcare, manufacturing, and technology. In addition, new technology, channel, and consulting partnerships enhanced Stonebranch’s capabilities and market reach.
Reflecting on the company's growth, Stonebranch CEO Giuseppe Damiani stated, "2023 was a pivotal year for Stonebranch. Our ability to attract and retain such a diverse clientele speaks volumes about our users' trust and confidence in our solutions. As organizations continue to navigate the complexities of digital transformation, Stonebranch continues to be a provider and partner of choice. It's inspiring to see such a wide array of organizations recognize the value of our solutions, and we’re excited to shape the future of IT automation with them.”
Universal Automation Center Elevates User Experience
Stonebranch introduced substantial enhancements to the Universal Automation Center (UAC) platform in 2023, focusing on elevating the user experience and broadening the scope of automation capabilities for IT Ops, DataOps, MLOps, and CloudOps professionals. Key highlights include the launch of:
- Observability with OpenTelemetry: UAC 7.5 introduced the OpenTelemetry connector, which makes telemetry data available via the OpenTelemetry standards. This feature collects log, metric, and trace data from UAC and third-party applications integrated with the UAC. Then, it outputs that collected data to application performance management (APM) tools (like Splunk, Dynatrace, and DataDog) and observability/business intelligence tools (like Grafana, Jaeger, and PowerBI).
- SAP Enhanced View: UAC has always made it easy for IT Ops teams to manage SAP tasks. With the release of UAC 7.5, Stonebranch extended this ease to business users too, by rolling out a new guided interface that’s intuitive for anyone who usually works with SAP ECC or S/4HANA.
- Jobs-as-Code: Building on UAC’s DevOps capabilities, jobs-as-code enables developers to manage jobs and workflow configuration just like business application code — directly from their integrated development environment (IDE) of choice. Additionally, by integrating UAC with source control repositories like GitHub, GitLab, and Azure DevOps, developers can establish continuous delivery pipelines that offer version control, testing capabilities, and CI/CD best practices.
- Strategic Integrations for a Connected Ecosystem: 2023 also marked the debut of several pivotal integrations, reinforcing Stonebranch's commitment to foster a more connected and agile IT ecosystem. New integrations include SAP IBP and SAP HANA XSA, DBT, Azure Synapse, SQL OBDC, Fivetran, Databricks, Temenos, Oracle EBS, Azure AZ CLI, Google Cloud Composer, and Red Hat OpenShift. These additions enhance UAC’s ability to seamlessly connect and orchestrate across diverse IT landscapes, driving unparalleled efficiency and innovation.
"Innovation is at the heart of everything we do at Stonebranch,” says Stonebranch CTO Peter Baljet. “Our commitment as a product leader is driven by our customers' rapidly evolving needs as they adopt new IT landscape paradigms. Looking ahead, we aim to enable businesses with the full potential of automation, transforming their operations and setting new levels for agility, observability, and scalability."
Accolades Celebrate Excellence at Stonebranch
Stonebranch is consistently recognized for its innovation, leadership, and workplace culture by prestigious organizations and industry analysts. These accolades highlight Stonebranch's commitment to providing cutting-edge automation solutions and fostering a supportive, dynamic work environment. Some of the notable recognition Stonebranch received in 2023 include:
- Gartner®: The research and consulting firm recognized Stonebranch in a variety of reports and guides in 2023, such as the Market Guide for Service Orchestration and Automation Platforms (SOAPs), Data and Analytics Essentials: DataOps Report, Hype Cycle for IT Infrastructure and Operations (I&O), and more.
- EMA: As a Value Leader in the 2023 EMA Radar™ Report for Workload Automation and Orchestration, Stonebranch was recognized as a “top-tier orchestrator capable of automation on-premises and in the cloud.”
- G2: In its reports for workload automation and managed file transfer, the peer-review platform awarded Stonebranch three Leader badges, a High-Performer badge, and an Easiest Doing Business With badge.
- Atlanta Journal-Constitution / Energage: Based solely on employee feedback, Stonebranch was recognized as a Metro Atlanta Top Workplace for the second consecutive year.
“These awards and recognitions are not just milestones but also motivation for us at Stonebranch,” noted Damiani. “As we celebrate these achievements, we remain focused on pushing the boundaries of what's possible in IT automation and orchestration.”
About Stonebranch
Stonebranch builds IT orchestration and automation solutions that transform business IT environments from simple IT task automation into sophisticated, real-time business service automation. No matter the degree of automation, the Stonebranch platform is simple, modern, and secure. Using the Stonebranch Universal Automation Platform, enterprises can seamlessly orchestrate workloads and data across technology ecosystems and silos. Headquartered in Atlanta, Georgia, with points of contact and support throughout the Americas, Europe, and Asia, Stonebranch serves some of the world’s largest financial, manufacturing, healthcare, travel, transportation, energy, and technology institutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227593444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
